Breast Cancer Patients Application Tamoxifen Clinical Analysis Of Endocrine Therapy With Fatty Liver

Breast cancer is a common carcinoma that threat for women’s health,according to statistics,the clinical incidence in female’s first tumor,and increased year by year.In the comprehensive therapy of breast cancer,endocrine therapy is extremely important.Tamoxifen as effective,using a line of endocrine therapy for the longest time,is widely used in clinical.Tamoxifen,a drug adverse reactions,now common clinical feedback are: gastrointestinal reaction,loss of appetite,nausea,vomiting,diarrhea;continue to anti-estrogen role,facial flush,menstrual disorders,amenorrhea,vaginal bleeding,etc.;Nerve mental symptoms,headache,dizziness,depression,etc.;Visual impairment;Bone marrow suppression,etc.Some literature suggests taking tamoxifen,lead to the occurrence of fatty liver.This article through the analysis to investigate the application of tamoxifen relationship with patients with fatty liver.1.Objective: The purpose of this paper is to analysis analysis to investigate the application of tamoxifen relationship with patients with fatty liver.2.Materials and methods: 2.1 Materials Retrospective review from our hospital between January 2013 and June 2015,a total of 150 cases of pathological diagnosis of breast cancer patients.Exclusion of alcoholic liver disease,viral genetic liver disease,hereditary liver disease,drug-induced liver disease,autoimmune disease,and other endocrine disease patients.The patient’s clinical diagnosis: 150 cases of unilateral breast cancer;Infiltrating ductal carcinoma of the 146 cases of mucous adenocarcinoma in 1 cases,gland scale cancer in 2 cases,signet ring cell carcinoma in 1 case.Pathological diagnosis: estrogen receptor,104 cases,negative in 46 cases;Progesterone receptor,73 cases,77 cases negative.Divided into 75 cases of experimental group and 75 cases of control group.Experimental group aged 41-77 years,mean age was 49.57±6.232 years;The control group,aged 43-79 at an average age of 50.12±5.176 years.Profile of the two groups of patients there was no statistically significant difference(P > 0.05),comparable.2.2 Methods The experimental group oral tamoxifen as endocrine therapy.Control group without using hormone therapy.Confirmed(drug treatment),after 1 months,6 months 12 months and 18 months,early in the morning on an empty stomach blood test ALT,AST,GGT,CHOL,review the Abdominal ultrasound or abdominal CT.3.Results Experimental AST levels,CHOL,abdominal ultrasound or abdominal CT indicate higher fatty liver cases,and the treatment before the difference was statistically significant(P < 0.05),ALT and GGT levels and there was no statistically significant difference before treatment(P > 0.05).The control level of ALT,AST,GGT level and abdominal ultrasound or abdominal CT prompt fatty liver cases there was no statistically significant difference with before treatment(P > 0.05).Multiple index analysis showed: breast cancer tamoxifen treatment can cause the occurrence of fatty liver.4.Conclusion: The study suggests taking tamoxifen as endocrine can cause the occurrence of fatty liver.Recommended in patients with endocrine therapy,regular checks liver function,the occurrence of early intervention of fatty liver.